| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | glcB |
| Uniprot No | P37330 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-723aa |
| 氨基酸序列 | SQTITQSRLRIDANFKRFVDEEVLPGTGLDAAAFWRNFDEIVHDLAPENRQLLAERDRIQAALDEWHRSNPGPVKDKAAYKSFLRELGYLVPQPERVTVETTGIDSEITSQAGPQLVVPAMNARYALNAANARWGSLYDALYGSDIIPQEGAMVSGYDPQRGEQVIAWVRRFLDESLPLENGSYQDVVAFKVVDKQLRIQLKNGKETTLRTPAQFVGYRGDAAAPTCILLKNNGLHIELQIDANGRIGKDDPAHINDVIVEAAISTILDCEDSVAAVDAEDKILLYRNLLGLMQGTLQEKMEKNGRQIVRKLNDDRHYTAADGSEISLHGRSLLFIRNVGHLMTIPVIWDSEGNEIPEGILDGVMTGAIALYDLKVQKNSRTGSVYIVKPKMHGPQEVAFANKLFTRIETMLGMAPNTLKMGIMDEERRTSLNLRSCIAQARNRVAFINTGFLDRTGDEMHSVMEAGPMLRKNQMKSTPWIKAYERNNVLSGLFCGLRGKAQIGKGMWAMPDLMADMYSQKGDQLRAGANTAWVPSPTAATLHALHYHQTNVQSVQANIAQTEFNAEFEPLLDDLLTIPVAENANWSAQEIQQELDNNVQGILGYVVRWVEQGIGCSKVPDIHNVALMEDRATLRISSQHIANWLRHGILTKEQVQASLENMAKVVDQQNAGDPAYRPMAGNFANSCAFKAASDLIFLGVKQPNGYTEPLLHAWRLREKESH |
| 预测分子量 | 84.4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于glcB重组蛋白的3篇参考文献示例(文献信息为模拟内容，供参考)：
1. **《Heterologous expression and characterization of Escherichia coli glcB-encoded malate synthase G》**
- 作者：Smith A, et al.
- 摘要：研究通过在大肠杆菌中异源表达glcB基因，成功纯化重组苹果酸合酶G，并分析其酶学特性，证明其在乙醛酸循环中的高效催化活性。
2. **《Optimization of glcB recombinant protein production in Pichia pastoris for industrial applications》**
- 作者：Zhang L, et al.
- 摘要：利用毕赤酵母系统优化glcB重组蛋白表达条件，实现高产量可溶性蛋白，为生物合成途径中乙醛酸代谢的规模化应用提供基础。
3. **《Functional analysis of glcB in Mycobacterium tuberculosis: Implications for persister cell metabolism》**
- 作者：Gupta R, et al.
- 摘要：通过构建结核分枝杆菌glcB重组蛋白突变株，揭示该酶在持留菌代谢适应中的关键作用，为抗结核药物靶点研究提供依据。
注：以上文献信息为示例，实际研究中建议通过PubMed或Web of Science等平台检索具体文献。
**Background of GlcB Recombinant Protein**
The *glcB* gene encodes malate synthase G, a key enzyme in the glyoxylate cycle, a metabolic pathway critical for the survival of microorganisms under carbon-limiting conditions. This cycle allows organisms to utilize simple carbon substrates, such as acetate or fatty acids, by bypassing the carbon-loss steps of the tricarboxylic acid (TCA) cycle. Malate synthase G catalyzes the condensation of glyoxylate with acetyl-CoA to form malate, enabling the net synthesis of carbohydrates from acetyl-CoA. This pathway is particularly vital for pathogens like *Mycobacterium tuberculosis*, which relies on the glyoxylate cycle during persistent infection in nutrient-scarce host environments.
Recombinant GlcB protein is produced through heterologous expression in bacterial systems (e.g., *E. coli*), enabling large-scale purification for functional and structural studies. Its production supports research into microbial metabolism, antibiotic development, and industrial biotechnology. For instance, inhibiting GlcB has been explored as a therapeutic strategy against tuberculosis, as disrupting the glyoxylate cycle compromises bacterial survival in hosts.
Structurally, GlcB belongs to the malate synthase family, sharing conserved catalytic domains but differing in regulatory mechanisms from its isoform, malate synthase A (GlcA). Studies on recombinant GlcB have elucidated its enzymatic kinetics, substrate specificity, and allosteric regulation, providing insights into evolutionary adaptations of metabolic pathways. Additionally, GlcB has applications in synthetic biology for engineering carbon-efficient microbial strains to optimize biofuel or biochemical production.
Overall, GlcB recombinant protein serves as a pivotal tool for understanding microbial physiology, pathogen resilience, and metabolic engineering, bridging fundamental research with translational innovations.
×
